Investitionsthese
Patient capital for challenger companies in Europe and the US, enabling operational partnership to drive long-term value in healthcare, software, and climate sectors.
Investitionsphase
All stages (growth-focused)
Bevorzugte Reifephase für die erste Finanzierung.
Sektoren & Themen
Technology-enabled businesses
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Ticketgröße
€48.760.000 - €147.200.000
Standard-Finanzierungsbetrag pro Runde.
Outreach & Dossier-Analysen
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
Investment Team (24)
A
Akhil Chainwala
Investment Director
A
Ala Alenazi
Investments
A
Ala Alenazi, PhD
Investments
A
Amanda Hillström
Investments
A
Andreas Bernström
Senior Investment Director
A
Andrey Simeonov
Investments
A
Andrey Simonov
Health & Bio Team
A
Anna Adlarson
Investments
A
Anna Adlarsson
Partner
C
Charles Martin
Partner
C
Chris Bischoff
Investment Professional
C
Christian Scherrer
Senior Investment Director
C
Cristina Stenbeck
Chairman of the Board
G
Georgi Ganev
CEO
J
Jose Gaytan de Ayala
XX
J
José Gaytán de Ayala
Investment Manager
L
Lucinda Palmer
Investments
M
Maria Helen Maras
Health & Bio team member
M
Maria Maras
Health & Bio Team
M
Maria-Helen Maras
Investments
N
Natalie Tydeman
Managing Investment Director
S
Sam Marsden
Climate Tech team member
S
Samuel Marsden
Investments
T
Tatiana Shalalvand
Investment Director
